Loading...
•
Mar 31, 2023
Checkpoint Therapeutics Q1 2023 Earnings Report
Checkpoint Therapeutics reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
Checkpoint Therapeutics announced the FDA accepted the BLA filing for cosibelimab in March and is preparing for a potential commercial launch in 2024. The company is also progressing active discussions with third parties to evaluate potential partnerships and other corporate development transactions.
FDA accepted the BLA filing for cosibelimab for metastatic or locally advanced cutaneous squamous cell carcinoma.
PDUFA goal date of January 3, 2024, was set for cosibelimab.
Checkpoint is preparing for a potential commercial launch in 2024.
Active discussions are ongoing with multiple third parties regarding potential partnerships and other corporate development transactions.
Forward Guidance
The press release contains forward-looking statements regarding the FDA review of the BLA for cosibelimab, the commercial potential of cosibelimab if approved, and projections of publication and regulatory review timelines.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...